Changes in Liver Fibrosis as Determined by FIB-4 Score Following Sofosbuvir-Based Treatment Regimes Without Interferon
Keywords:
Transient Elastography (TE), Liver Fibrosis, Sofosbuvir, Direct-acting antivirals (DAAs)Abstract
Objective: To determine the mean change in liver fibrosis as evaluated using the FIB-4 score following Sofosbuvir based treatment regimens without interferon.
Methodology: This prospective observational study was conducted at the Department of Medicine, Federal Government Services Hospital, Islamabad, from January 09, 2019 to January 03, 2020. A total of seventy (n=70) patients of either gender between age 18-75 years who were diagnosed with cases of HCV infection were enrolled in this study. All patients were treated with Sofosbuvir-based treatment regimens and were assessed for liver fibrosis using the FIB-4 score at baseline, at end of treatment (EOT) and 12 weeks after EOT.
Results: The mean FIB-4 score at baseline was 2.45±0.42, at EOT was 1.0981±0.33 and at 12 weeks after EOT was 1.51±0.32. As compared to the baseline, the mean FIB-4 score was significantly lesser at EOT (P=0.001) and at 12 weeks after EOT (P=0.001). A similar trend was observed across all stratified groups, i.e., age, gender, and type of patients (P<0.05 across all groups).
Conclusion: The sofosbuvir-based treatment regimen significantly reduced liver fibrosis at EOT and 12 weeks after EOT, as evidenced by FIB-4 scores that were significantly lower than baseline at EOT and 12 weeks after EOT.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Maria Zafar, Hannan Zulfiqar, Muhammad Najm ul Hasan Shafi , Hassam Zulfiqar, Raja Sheraz Ullah Khan, Muhammad Bilal Shafi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.